| scholarly article | Q13442814 |
| P50 | author | Barton Haynes | Q4865631 |
| David C. Montefiori | Q63302725 | ||
| Hua-Xin Liao | Q88608388 | ||
| John C Kappes | Q92482518 | ||
| Tara G Edmonds | Q125313695 | ||
| P2093 | author name string | Christina Ochsenbauer | |
| Anthony R Geonnotti | |||
| Xing Yuan | |||
| Miroslawa Bilska | |||
| P2860 | cites work | Microbial translocation is a cause of systemic immune activation in chronic HIV infection | Q22251054 |
| HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes | Q22252313 | ||
| TLR4 mutations are associated with endotoxin hyporesponsiveness in humans | Q22254186 | ||
| Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in Tlr4 Gene | Q22299417 | ||
| Structures of human genes coding for cytokine LD78 and their expression | Q24300929 | ||
| Inhibition of HIV-1 infection by the beta-chemokine MDC | Q24309584 | ||
| The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry | Q24315492 | ||
| Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies | Q24561905 | ||
| Antibody domain exchange is an immunological solution to carbohydrate cluster recognition | Q27641517 | ||
| Structural analysis of the epitope of the anti-HIV antibody 2F5 sheds light into its mechanism of neutralization and HIV fusion | Q27641682 | ||
| Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product | Q28141458 | ||
| Pyogenic bacterial infections in humans with IRAK-4 deficiency | Q28183411 | ||
| LD78beta, a non-allelic variant of human MIP-1alpha (LD78alpha), has enhanced receptor interactions and potent HIV suppressive activity | Q28199341 | ||
| Diverging binding capacities of natural LD78beta isoforms of macrophage inflammatory protein-1alpha to the CC chemokine receptors 1, 3 and 5 affect their anti-HIV-1 activity and chemotactic potencies for neutrophils and eosinophils | Q28205971 | ||
| Macrophage inflammatory protein-1 | Q28211059 | ||
| Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. | Q28217208 | ||
| Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells | Q28270680 | ||
| CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein | Q29615189 | ||
| The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1 | Q29616093 | ||
| HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5 | Q29616094 | ||
| Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody | Q29618366 | ||
| Rapid evolution of the neutralizing antibody response to HIV type 1 infection | Q29618603 | ||
| Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies | Q29619015 | ||
| Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. | Q29619254 | ||
| Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection | Q29619510 | ||
| Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. | Q29622903 | ||
| Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. | Q31016954 | ||
| Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies | Q33274285 | ||
| Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients | Q33346244 | ||
| International network for comparison of HIV neutralization assays: the NeutNet report | Q33410826 | ||
| HIV-1 RNA dysregulates the natural TLR response to subclinical endotoxemia in Kenyan female sex-workers | Q33450665 | ||
| Differential sensitivities of Chlamydia trachomatis strains to inhibitory effects of gamma interferon | Q33593230 | ||
| Expression and use of human immunodeficiency virus type 1 coreceptors by human alveolar macrophages | Q33815704 | ||
| Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines | Q33911935 | ||
| Activation of human monocyte--derived macrophages with lipopolysaccharide decreases human immunodeficiency virus replication in vitro at the level of gene expression | Q34193240 | ||
| A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1 | Q34306804 | ||
| The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. | Q34341843 | ||
| The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120. | Q34342352 | ||
| HIV-1-suppressive factors are secreted by CD4+ T cells during primary immune responses | Q34389601 | ||
| Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells | Q35024276 | ||
| Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination | Q35208657 | ||
| Monoclonal antibodies to phosphatidylinositol phosphate neutralize human immunodeficiency virus type 1: role of phosphate-binding subsites | Q35635418 | ||
| Contribution of virion ICAM-1 to human immunodeficiency virus infectivity and sensitivity to neutralization | Q35887432 | ||
| Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12. off. | Q35892184 | ||
| LPS, TLR4 and infectious disease diversity. | Q35988748 | ||
| Interferons and bacterial lipopolysaccharide protect macrophages from productive infection by human immunodeficiency virus in vitro | Q36356182 | ||
| Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration. | Q36496923 | ||
| The LD78beta isoform of MIP-1alpha is the most potent CCR5 agonist and HIV-1-inhibiting chemokine | Q36736256 | ||
| Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens | Q36747750 | ||
| Methods of endotoxin removal from biological preparations: a review | Q36922614 | ||
| CD8+ T-cell-derived soluble factor(s), but not beta-chemokines RANTES, MIP-1 alpha, and MIP-1 beta, suppress HIV-1 replication in monocyte/macrophages | Q37093363 | ||
| Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination | Q37119451 | ||
| Cutting edge: Experimentally induced immune activation in natural hosts of simian immunodeficiency virus induces significant increases in viral replication and CD4+ T cell depletion | Q37224358 | ||
| Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: a specific role for antibodies against the membrane-proximal external region of gp41. | Q37256661 | ||
| Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection | Q37273158 | ||
| Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection | Q37309633 | ||
| New virologic reagents for neutralizing antibody assays | Q37667758 | ||
| Biological and physical characterization of the X4 HIV-1 suppressive factor secreted by LPS-stimulated human macrophages. | Q38354034 | ||
| The LD78beta isoform of MIP-1alpha is the most potent CC-chemokine in inhibiting CCR5-dependent human immunodeficiency virus type 1 replication in human macrophages | Q38877913 | ||
| Susceptibility of HIV type 1 to the fusion inhibitor T-20 is reduced on insertion of host intercellular adhesion molecule 1 in the virus membrane | Q38898638 | ||
| Inhibition of CXCR4-tropic HIV-1 infection by lipopolysaccharide: evidence of different mechanisms in macrophages and T lymphocytes | Q39557284 | ||
| HIV sensitivity to neutralization is determined by target and virus producer cell properties | Q39828346 | ||
| Measuring HIV neutralization in a luciferase reporter gene assay | Q39914262 | ||
| TLR2 signaling renders quiescent naive and memory CD4+ T cells more susceptible to productive infection with X4 and R5 HIV-type 1. | Q40079013 | ||
| CD14 and innate recognition of bacteria. | Q40402184 | ||
| A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. | Q40757568 | ||
| A CD14-independent LPS receptor cluster | Q40817738 | ||
| Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. | Q40832863 | ||
| A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. | Q41419602 | ||
| C-C chemokines released by lipopolysaccharide (LPS)-stimulated human macrophages suppress HIV-1 infection in both macrophages and T cells. | Q42172842 | ||
| Antibody-based HIV-1 vaccines: recent developments and future directions | Q42738983 | ||
| CCL3L1 and HIV/AIDS susceptibility | Q42910904 | ||
| Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections | Q43814365 | ||
| HIV-1 envelope pseudotyped viral vectors and infectious molecular clones expressing the same envelope glycoprotein have a similar neutralization phenotype, but culture in peripheral blood mononuclear cells is associated with decreased neutralization | Q43917129 | ||
| Virion-bound ICAM-1 and activated LFA-1: a combination of factors conferring resistance to neutralization by sera from human immunodeficiency virus type 1-infected individuals independently of the disease status and phase | Q45722197 | ||
| CD14 is required for MyD88-independent LPS signaling. | Q45990170 | ||
| Essential role of MD-2 in LPS responsiveness and TLR4 distribution. | Q50109313 | ||
| Human alpha- and beta-interferon but not gamma- suppress the in vitro replication of LAV, HTLV-III, and ARV-2. | Q55244180 | ||
| Recombinant human interferon alfa-A suppresses HTLV-III replication in vitro. | Q55245135 | ||
| Chemokines and HIV replication | Q60083211 | ||
| Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy | Q60220163 | ||
| Evidence for an accessory protein function for Toll-like receptor 1 in anti-bacterial responses | Q73306880 | ||
| Antiproliferative effects of retinoic acid/interferon in cervical carcinoma cell lines: cooperative growth suppression of IRF-1 and p53 | Q73396788 | ||
| Chemokine receptor 4 (CXCR4) is part of the lipopolysaccharide "sensing apparatus" | Q80201765 | ||
| A smooth operator for LPS responses | Q81772305 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | virology | Q7215 |
| immunology | Q101929 | ||
| endotoxins | Q319997 | ||
| infectious disease | Q18123741 | ||
| P304 | page(s) | 279-291 | |
| P577 | publication date | 2010-03-01 | |
| P1433 | published in | AIDS Research and Human Retroviruses | Q4651880 |
| P1476 | title | Differential inhibition of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and TZM-bl cells by endotoxin-mediated chemokine and gamma interferon production | |
| P478 | volume | 26 |
| Q37127735 | Antibodies to a superantigenic glycoprotein 120 epitope as the basis for developing an HIV vaccine |
| Q92146523 | Assessment of Antibody Interference of Enfuvirtide (T20) Function Shows Assay Dependent Variability |
| Q34597300 | Back to the future: covalent epitope-based HIV vaccine development |
| Q36469664 | CD4 binding determinant mimicry for HIV vaccine design |
| Q34053295 | Characterization of neutralizing profiles in HIV-1 infected patients from whom the HJ16, HGN194 and HK20 mAbs were obtained |
| Q58755636 | Comprehensive off-target analysis of dCas9-SAM-mediated HIV reactivation via long noncoding RNA and mRNA profiling |
| Q35915661 | Constitutively Active MAVS Inhibits HIV-1 Replication via Type I Interferon Secretion and Induction of HIV-1 Restriction Factors |
| Q34006748 | Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies |
| Q35903806 | Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells |
| Q35774679 | Development of a tier 1 R5 clade C simian-human immunodeficiency virus as a tool to test neutralizing antibody-based immunoprophylaxis |
| Q28743559 | Exposure to apoptotic activated CD4+ T cells induces maturation and APOBEC3G-mediated inhibition of HIV-1 infection in dendritic cells |
| Q36530370 | GB virus type C envelope protein E2 elicits antibodies that react with a cellular antigen on HIV-1 particles and neutralize diverse HIV-1 isolates |
| Q34412302 | Identification and characterization of a broadly cross-reactive HIV-1 human monoclonal antibody that binds to both gp120 and gp41. |
| Q39229789 | Immunization with hybrid proteins containing the membrane proximal external region of HIV-1. |
| Q42241364 | Mitigation of variation observed in a peripheral blood mononuclear cell (PBMC) based HIV-1 neutralization assay by donor cell pooling |
| Q38972386 | Molecular modeling, synthesis and biological evaluation of N-heteroaryl compounds as reverse transcriptase inhibitors against HIV-1. |
| Q34253227 | Multivalent dendrimeric compounds containing carbohydrates expressed on immune cells inhibit infection by primary isolates of HIV-1. |
| Q33693391 | Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. |
| Q35732677 | Purification and functional characterization of mucosal IgA from vaccinated and SIV-infected rhesus macaques |
| Q90628352 | TLR4-Mediated Pathway Triggers Interferon-Independent G0 Arrest and Antiviral SAMHD1 Activity in Macrophages |
| Q64885907 | The Pre-clinical Toolbox of Pharmacokinetics and Pharmacodynamics: in vitro and ex vivo Models. |
Search more.